Research Areas 12 min read

GLP-1 Peptides: Complete Research Guide (Semaglutide, Tirzepatide, Retatrutide)

GLP-1 receptor agonists represent one of the most significant advances in metabolic medicine in decades. This guide covers the research landscape for GLP-1 peptides, from the biology of the incretin axis to the latest triple-receptor agonists.

The Incretin Axis: Biological Background

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by L-cells in the intestinal mucosa in response to nutrient ingestion. It acts on GLP-1 receptors in the pancreas, brain, heart, and gastrointestinal tract to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. The GLP-1 receptor is a class B G protein-coupled receptor (GPCR) that activates adenylyl cyclase and increases intracellular cAMP. Native GLP-1 has a very short half-life (~2 minutes) due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). Research peptides in this class are synthetic analogs engineered to resist DPP-4 degradation, dramatically extending their half-life and enabling once-weekly dosing in clinical applications.

Semaglutide: The Reference GLP-1 Agonist

Semaglutide is a 31-amino acid GLP-1 analog with 94% sequence homology to native GLP-1. Its extended half-life (~7 days) is achieved through C-18 fatty acid conjugation via a linker, enabling albumin binding and reduced renal clearance. In the SUSTAIN and STEP clinical trial programs, semaglutide demonstrated significant HbA1c reduction and body weight loss of approximately 15% in obese subjects. The SURMOUNT-1 trial for tirzepatide subsequently showed superior outcomes (~20-22% weight loss), positioning semaglutide as the established benchmark against which newer agents are compared. For researchers, semaglutide is the best-characterized GLP-1 agonist with the largest published literature base.

Tirzepatide: Dual GIP/GLP-1 Agonism

Tirzepatide represents the next generation of incretin research — a dual agonist targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The addition of GIP agonism was initially controversial, as GIP was thought to be less effective in obese individuals. However, tirzepatide's clinical results exceeded expectations, with the SURMOUNT program demonstrating weight loss of 20-22% — substantially greater than semaglutide. The mechanistic basis for this superiority is still being elucidated, but appears to involve synergistic effects on adipose tissue metabolism, energy expenditure, and central appetite regulation. Tirzepatide is now approved as Mounjaro (T2D) and Zepbound (obesity) and is a major focus of ongoing research.

Retatrutide: Triple Receptor Agonism

Retatrutide (LY3437943) is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 clinical trial data published in the New England Journal of Medicine (2023) demonstrated weight loss of up to 24.2% at 48 weeks — the highest reported for any pharmacological agent to date. The addition of glucagon receptor agonism to the dual incretin mechanism is hypothesized to increase energy expenditure and hepatic fat mobilization. Retatrutide is currently in Phase 3 trials and represents the leading edge of incretin-based peptide research. For researchers studying metabolic peptides, retatrutide exemplifies the progression from single to multi-receptor targeting strategies.

Quality documentation toolkit

Continue your COA review

Use the same repeatable documentation checks across every research peptide review. COA Check organizes visible document fields; laboratory verification remains the route for authenticity confirmation.

Research Use Only: All information in this guide is provided for educational and scientific research purposes only. Content does not constitute medical advice. Always consult a qualified healthcare professional before making any health-related decisions.